Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityActive in the last 2 years

Dansong Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8406-3222; OpenAlex author ID A5084750305. Sources: OpenAlex.

Their work

Papers
38 (first author 2, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
75
Papers, trials and grants by year

2012: 3 papers · 2013: 2 papers · 2014: 1 paper · 2015: 2 papers · 2016: 4 papers · 2017: 2 papers · 2018: 4 papers · 2019: 5 papers · 2020: 2 papers · 2021: 3 papers · 2022: 3 papers · 2023: 3 papers · 2024: 2 papers · 2025: 2 papers

Papers 38

  1. Pancreatic surgery is safe in elderly patients with PDAC. Co-author DOI 10.1186/s12877-025-05907-8↗
  2. Deciphering molecular crosstalk mechanisms between skeletal muscle atrophy and KRAS-mutant pancreatic cancer: a literature review. Co-author DOI 10.21037/hbsn-24-282↗
  3. Circulating cell-free DNA methylation-based multi-omics analysis allows early diagnosis of pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/1878-0261.13643↗
  4. Efficacy of nab‑paclitaxel vs. Gemcitabine in combination with S‑1 for advanced pancreatic cancer: A multicenter phase II randomized trial. Co-author DOI 10.3892/ol.2024.14293↗
  5. NEDD8-Activating Enzyme Inhibitor MLN4924 Inhibits Both the Tumor Stroma and Angiogenesis in Pancreatic Cancer via Gli1 and REDD1. Co-author DOI 10.1007/s10620-022-07671-w↗
  6. Retraction Note: MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41598-023-48852-5↗
  7. Additional adjuvant radiotherapy improves survival at 1 year after surgical treatment for pancreatic cancer patients with T4, N2 disease, positive resection ma… Co-author DOI 10.3389/fonc.2023.1109068↗
  8. GFAT1 is highly expressed in cancer stem cells of pancreatic cancer. Co-author DOI 10.21037/atm-22-1946↗
  9. Prognostic Effect of Age in Resected Pancreatic Cancer Patients: A Propensity Score Matching Analysis. Co-author DOI 10.3389/fonc.2022.789351↗
  10. PYCR1: A Potential Prognostic Biomarker in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.7150/jca.61498↗
  11. Basal microvilli define the metabolic capacity and lethal phenotype of pancreatic cancer. Co-author DOI 10.1002/path.5588↗
  12. Prognostic value of preoperative glucose to lymphocyte ratio in patients with resected pancreatic cancer. Co-author DOI 10.1007/s10147-020-01782-y↗
  13. Gut-derived lipopolysaccharide remodels tumoral microenvironment and synergizes with PD-L1 checkpoint blockade via TLR4/MyD88/AKT/NF-κB pathway in pancreatic c… Co-author DOI 10.1038/s41419-021-04293-4↗
  14. Preoperative radiotherapy improves overall survival of pT4 pancreatic ductal adenocarcinoma patients after surgical resection. Co-author DOI 10.1093/jjco/hyaa035↗
  15. Current Role of Surgery in Pancreatic Cancer With Synchronous Liver Metastasis. First author DOI 10.1177/1073274820976593↗
  16. TRAF6 regulates YAP signaling by promoting the ubiquitination and degradation of MST1 in pancreatic cancer. Co-author DOI 10.1007/s10238-018-00543-6↗
  17. Cell-intrinsic PD-1 promotes proliferation in pancreatic cancer by targeting CYR61/CTGF via the hippo pathway. Co-author DOI 10.1016/j.canlet.2019.06.013↗
  18. Exosomal miRNA-106b from cancer-associated fibroblast promotes gemcitabine resistance in pancreatic cancer. Co-author DOI 10.1016/j.yexcr.2019.111543↗
  19. Laparoscopic versus open pancreaticoduodenectomy for pancreatic ductal adenocarcinoma: a propensity score matching analysis. Co-author DOI 10.1186/s40880-019-0410-8↗
  20. Independent effect of postoperative neutrophil-to-lymphocyte ratio on the survival of pancreatic ductal adenocarcinoma with open distal pancreatosplenectomy an… Co-author DOI 10.7150/jca.35856↗
  21. Chk1 inhibitor SCH 900776 enhances the antitumor activity of MLN4924 on pancreatic cancer. Co-author DOI 10.1080/15384101.2017.1405194↗
  22. Efficacy and safety comparison of nabpaclitaxel plus S-1 and gemcitabine plus S-1 as first-line chemotherapy for metastatic pancreatic cancer. Co-author DOI 10.1093/jjco/hyy063↗
  23. CD25 and TGF-β blockade based on predictive integrated immune ratio inhibits tumor growth in pancreatic cancer. Co-author DOI 10.1186/s12967-018-1673-6↗
  24. Survival prediction in pancreatic cancer patients with no distant metastasis: a large-scale population-based estimate. Co-author DOI 10.2217/fon-2017-0380↗
  25. SF3B4 is decreased in pancreatic cancer and inhibits the growth and migration of cancer cells. Last author DOI 10.1177/1010428317695913↗
  26. Alkaline Phosphatase-To-Albumin Ratio as a Prognostic Indicator in Pancreatic Ductal Adenocarcinoma after Curative Resection. Co-author DOI 10.7150/jca.20917↗
  27. Low intratumoral regulatory T cells and high peritumoral CD8(+) T cells relate to long-term survival in patients with pancreatic ductal adenocarcinoma after pa… Co-author DOI 10.1007/s00262-015-1775-4↗
  28. MicroRNA-454 regulates stromal cell derived factor-1 in the control of the growth of pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/srep22793↗
  29. ITRAQ-based quantitative proteomics reveals apolipoprotein A-I and transferrin as potential serum markers in CA19-9 negative pancreatic ductal adenocarcinoma. Co-author DOI 10.1097/md.0000000000004527↗
  30. Increased expression of αTubulin is associated with poor prognosis in patients with pancreatic cancer after surgical resection. Co-author DOI 10.18632/oncotarget.10630↗
  31. Long-term survival following total pancreatectomy and superior mesenteric-portal vein resection for pancreatic ductal adenocarcinoma: A case report. Co-author DOI 10.3892/ol.2014.2628↗
  32. LIN28B suppresses microRNA let-7b expression to promote CD44+/LIN28B+ human pancreatic cancer stem cell proliferation and invasion. Co-author PMID 26609473↗
  33. TRAF6 is over-expressed in pancreatic cancer and promotes the tumorigenicity of pancreatic cancer cells. First author DOI 10.1007/s12032-014-0260-9↗
  34. Lipocalin-2 is associated with a good prognosis and reversing epithelial-to-mesenchymal transition in pancreatic cancer. Last author DOI 10.1007/s00268-013-2009-6↗
  35. Lactate dehydrogenase A is overexpressed in pancreatic cancer and promotes the growth of pancreatic cancer cells. Co-author DOI 10.1007/s13277-013-0679-1↗
  36. Treatment of pancreatic cancer using an oncolytic virus harboring the lipocalin-2 gene. Co-author DOI 10.1002/cncr.27535↗
  37. A phase I pilot trial of MUC1-peptide-pulsed dendritic cells in the treatment of advanced pancreatic cancer. Co-author DOI 10.1007/s10238-011-0159-0↗
  38. Primary small cell carcinoma of the pancreas: rare type of pancreatic cancer and review of the literatures. Co-author DOI 10.1186/1477-7819-10-32↗

Closest collaborators

The 25 strongest of 75 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Wenchuan Wu · 25 shared papers, 2012–2025 · strength 2.54
  2. Tiantao Kuang · 23 shared papers, 2012–2024 · strength 2.36
  3. Dayong Jin · 21 shared papers, 2012–2024 · strength 1.78
  4. Xuefeng Xu · 15 shared papers, 2015–2024 · strength 1.68
  5. Wenhui Lou · 12 shared papers, 2014–2024 · strength 1.39
  6. Yefei Rong · 15 shared papers, 2012–2024 · strength 1.36
  7. Yaolin Xu · 8 shared papers, 2018–2025 · strength 1.29
  8. Wenhui Lou · 13 shared papers, 2012–2025 · strength 1.28
  9. Wenhui Lou · 9 shared papers, 2013–2025 · strength 1.02
  10. Yueming Zhang · 4 shared papers, 2020–2025 · strength 0.67
  11. Ning Pu · 7 shared papers, 2017–2021 · strength 0.60
  12. Xu Han · 3 shared papers, 2019–2025 · strength 0.45
  13. Wentao Zhou · 4 shared papers, 2017–2020 · strength 0.44
  14. Lei Zhang · 2 shared papers, 2023–2025 · strength 0.44
  15. Jianang Li · 4 shared papers, 2017–2023 · strength 0.42
  16. Liang Liu · 2 shared papers, 2024–2025 · strength 0.40
  17. Xi Guo · 3 shared papers, 2018–2024 · strength 0.40
  18. Lili Wu · 3 shared papers, 2018–2024 · strength 0.40
  19. Hanlin Yin · 4 shared papers, 2018–2021 · strength 0.37
  20. Weilin Mao · 2 shared papers, 2022–2023 · strength 0.34
  21. Yuhong Zhou · 2 shared papers, 2024 · strength 0.33
  22. Yue Fan · 3 shared papers, 2016–2023 · strength 0.31
  23. Deliang Fu · 2 shared papers, 2021–2024 · strength 0.30
  24. Ding-Fang Cai · 2 shared papers, 2016–2023 · strength 0.29
  25. Chenye Shi · 2 shared papers, 2016–2023 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.